A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis

Clinical Trial

J C Mansfield et al. Aliment Pharmacol Ther. 2002 Jan.

Free article

Abstract

Background: Sulfasalazine is accepted therapy for active ulcerative colitis, but side-effects and intolerance are common. Balsalazide is an azo-bonded pro-drug which also releases 5-aminosalicylic acid into the colon, but uses an inert carrier molecule.

Aim: To compare the safety and efficacy of sul- fasalazine, 3 g, with balsalazide, 6.75 g, in the initial daily treatment of mild to moderate ulcerative colitis.

Methods: A randomized, multicentre, double-blind, parallel group study was performed, with a treatment duration of 8 weeks. Patients on previous maintenance treatment were excluded. The trial medication was the sole treatment for the colitis. Efficacy was assessed by patient diaries, symptom assessment, sigmoidoscopic appearance and histology.

Results: Fifty patients were recruited: 26 allocated to the balsalazide group and 24 to the sulfasalazine group. More patients withdrew due to adverse events in the sulfasalazine group (nine patients vs. one patient in the balsalazide group, P=0.004). Improvement occurred in both groups, with a tendency to a faster response with balsalazide. Of the patients taking balsalazide, 61% achieved clinical and sigmoidoscopic remission.

Conclusions: Balsalazide, 6.75 g, is effective as the sole treatment for patients with mild to moderately active ulcerative colitis, with significantly fewer withdrawals due to side-effects than in a similar group of patients taking sulfasalazine, 3 g.

PubMed Disclaimer

Cited by

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α.
Park J, Cheon JH. Park J, et al. Korean J Intern Med. 2022 Sep;37(5):895-905. doi: 10.3904/kjim.2022.132. Epub 2022 Jul 27. Korean J Intern Med. 2022. PMID: 35882566 Free PMC article. Review.
First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus.
Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. Alkhatry M, et al. World J Gastroenterol. 2020 Nov 21;26(43):6710-6769. doi: 10.3748/wjg.v26.i43.6710. World J Gastroenterol. 2020. PMID: 33268959 Free PMC article.
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Murray A, et al. Cochrane Database Syst Rev. 2020 Aug 12;8(8):CD000543. doi: 10.1002/14651858.CD000543.pub5. Cochrane Database Syst Rev. 2020. PMID: 32786164 Free PMC article.
Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease.
Sood A, Ahuja V, Midha V, Sinha SK, Pai CG, Kedia S, Mehta V, Bopanna S, Abraham P, Banerjee R, Bhatia S, Chakravartty K, Dadhich S, Desai D, Dwivedi M, Goswami B, Kaur K, Khosla R, Kumar A, Mahajan R, Misra SP, Peddi K, Singh SP, Singh A. Sood A, et al. Intest Res. 2020 Oct;18(4):355-378. doi: 10.5217/ir.2019.09176. Epub 2020 Jul 13. Intest Res. 2020. PMID: 32646198 Free PMC article. Review.
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H; IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. Lamb CA, et al. Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27. Gut. 2019. PMID: 31562236 Free PMC article. Review.

A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis - PubMed (original) (raw)